KDM1A and hepatocellular carcinoma: Suppression of KDM1A might be an attractive target for regorafenib sensitization and clinical HCC therapy, but an in-depth mechanistic investigation is lacking.199 Further research proved that KDM1A inhibitors, such as pargyline and GSK2879552, dramatically suppress the stem-like properties of sorafenib-resistant HCC cells, including resensitization to sorafenib.